In a small but meaningful number of patients, Gleason pattern 4 disease missed by MRI and systematic biopsy is present outside the focal ablation zone.
Family history does not predict aggressiveness of prostate cancer or suitability for active surveillance as a treatment option.
African American men choosing active surveillance for their low-grade prostate cancer have overall poorer health than non-African American men undergoing active surveillance.
Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net HospitalsFebruary 24, 2017
A significant difference exists in the failure to follow-up rates among patients undergoing active surveillance at university-based hospitals versus safety-net hospitals.
Researchers analyzed data from the NPCR of Sweden to determine whether more US men with prostate cancer would choose active surveillance if it were presented as a treatment option.
Disease-specific mortality rates for men with prostate cancer are comparable for 3 treatment options: active surveillance, radical prostatectomy, and external-beam radiotherapy.
Ethnicity influences patient decision to pursue active treatment and serial biopsies in active surveillance
Patients with slow-growing prostate cancer are increasingly opting for active surveillance and only changing treatment plan if the disease changes to a higher risk form to avoid unnecessary and potentially toxic treatments.
African American men with Gleason score 3+3=6 prostate cancer produce less PSA and have significantly lower PSA density than white men, according to a new study. These findings could have important implications for treatment decision-making.
Higher radiation dose is associated with improved survival rates among men with medium- and high-risk prostate cancer.
An analysis of data on 945 patients with prostate cancer followed with active surveillance displayed outcome differences, depending on whether the patient was low- or intermediate-risk at diagnosis.
New research suggests that active surveillance may be an initial approach for men with favorable intermediate-risk prostate cancer.
Active surveillance allows men with prostate cancer to delay or avoid the side effects of its treatment as well.
The level of expression of three genes associated with aging can be used to predict whether seemingly low-risk prostate cancer will remain slow growing, according to new research.
The proportion of men with advanced-stage prostate tumors at diagnosis has dropped dramatically since the widespread implementation of PSA screening, but the proportion of men with aggressive cancers at diagnosis has not changed substantially.
A clinic-based technique of targeted biopsy using MRI and ultrasound may improve the diagnosis and management of prostate cancer.
Active surveillance of small kidney masses is a safe and effective alternative to immediate surgery. The overall and cancer specific survival rates are similar for both approaches.
Sign Up for Free e-newsletters
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Distinct Patterns of Shiny White Streaks Strong Indicator of Melanoma
- Survival Outcomes in Relapsed Hepatocellular Carcinoma Improved With Cabozantinib
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- When There Are No Words: Interpreting Patients' and Families' Subtle Messages
- Depression Predictive of Poor Survival Outcomes in Head and Neck Cancer
- Nearly One Third of Veterans Report Current Tobacco Use
- Priority Review of New Drug Application Granted to Apalutamide for CRPC
- Partial Response Achieved With Atezolizumab, Cobimetinib in Pretreated CRC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|